Novo Holdings, a leading international life sciences investor, today announced a significant investment in 21st.BIO A/S – a new Danish bioindustrial scale-up company.

The technology platform of 21st.BIO originates from selected parts of Novozymes platform, which has been developed and perfected over the past 40+ years. Established in 2020, 21st.BIO has been founded with a mission to support bioindustrial companies globally in upscaling from molecule innovation to large-scale production to be able to meet market demands and thereby advance the green transition globally.

https://www.21st.com/

Financial Services

Software

Copenhagen, Capital Region Of Denmark, Denmark

Novo Holdings Invests Eur 86 Million In 21St.Bio, A New Bioindustrial Scale-Up Company Building On Technology Base From Novozymes

Description

Company Information

Funding Insights

Novo Holdings Invests Eur 86 Million In 21St.Bio, A New Bioindustrial Scale-Up Company Building On Technology Base From Novozymes

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information